Radius Business Update

December 8, 2021

Radius®

Safe Harbor

Any statements made in this presentation relating to future financial or business performance, guidance, conditions, plans, prospects, trends or strategies and other financial or business matters are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when used in this presentation, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predicts”, “targets” and similar expressions and their variants, as they relate to Radius Health, Inc. (“Radius”) or its management, may identify forward-looking statements. Radius cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by Radius to secure and maintain relationships with collaborators; risks relating to clinical trials; risks relating to the commercialization of TYMLOS in the U.S., or potential commercialization of any of Radius’ or Menarini Group’s proposed product candidates if approved, (such as marketing, regulatory, patent, product liability, supply, competition and other risks); the impacts of the ongoing COVID-19 pandemic on our business, results of operations, and financial condition; dependence on the efforts of third parties, including Menarini Group in the development and commercialization of elacestrant; dependence on and challenges to our intellectual property rights; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect Radius’ business, financial conditions and results of operations and could cause actual results to differ materially from those indicated by the forward-looking statements made in this presentation are contained under the caption “risk factors” in Radius’ Annual Report on Form 10-K for the period ended December 31, 2020, along with Radius’ other reports filed with the Securities and Exchange Commission. The forward-looking statements in this presentation represent Radius’ estimate as of the date of this presentation only, and Radius specifically disclaims any duty or obligation to update forward-looking statements.

Within this presentation, in order to provide greater transparency regarding our performance, we refer to certain non-GAAP financial measures that involve adjustments to GAAP measures. Any non-GAAP financial measures presented should not be considered an alternative to measures required by GAAP and are unlikely to be comparable to non-GAAP information provided by other companies. A reconciliation between our non-GAAP financial measures and GAAP financial measures is included at the end of this presentation.

Radius

Agenda

- Opening Comments
- Elacestrant
- Abaloparatide-TDS
- What does this mean for Radius?
- Q&A

Opening Comments

Elacestrant

- Partnered Program: Menarini owner; Radius will support until NDA filing
- Data: monotherapy vs. SoC in two patient groups: overall & ESR1 mutant
- Safety Results
- Life Cycle: additional indication(s) and combination(s)
- Radius Economics: Milestones & Royalties: global and ‘in any form’

Abaloparatide-TDS

- Did not achieve primary endpoint of non-inferiority vs. TYMLOS®
- BMD improvement in both primary and secondary endpoints (spine and hip)
- Safety Results: TEAEs similar in both groups
- Clinical data and technical assessment on-going

Radius

Elacestrant

EMERALD Study Results

- In overall population, reduced risk of progression or death by 30% vs. SoC
- In mESR1 population, reduced risk of progression or death by 45% vs. SoC
- PFS rate at 12 months with elacestrant: 22.32% vs. 9.42% with SoC in overall population and 26.76% vs. 8.19% in mESR1 population
- Vs. fulvestrant, reduced risk of progression or death by 32% in overall population and 50% in mESR1
- Elacestrant was well tolerated with an encouraging safety profile consistent with other ETs

LCM Activity

- Plan to test elacestrant in earlier treatment lines, including the adjuvant setting and combination trials
- Planned Phase 2 study, ELECTRA, where elacestrant will be tested in combination with abemaciclib in patients with ER-positive/HER2-negative metastatic breast cancer that has metastasized to the brain

Radius

Abaloparatide-TDS wearABLe Data

- Abalo-TDS did not demonstrate non-inferiority to TYMLOS in wearABLe
- Spine BMD vs. baseline for abalo-TDS was +7.1% vs. TYMLOS +10.9%
  - Treatment difference: -3.7% (95% CI: -5.0, -2.4)
- Total hip and femoral neck BMD increased by avg. of 2.0% and 1.9% for abalo-TDS and by an avg. of 3.7% and 3.4% for TYMLOS
- Both Abalo-TDS and TYMLOS' results are considered clinically meaningful
- Abalo-TDS was well tolerated with no significant safety signals identified
- TYMLOS exceeded efficacy expectations in wearABLe trial

Radius

Abaloparatide-TDS Next Steps

1) First Step

- Full assessment of all detailed clinical data

2) Pre-requisites IF we are to move abalo-TDS ‘next gen’ forward:

- Regulatory Discussion: 100% clarity on any future pivotal program
- Business: Re-construct Supply Chain Agreement, Economics & Risk
- Capital: financing – will not fund through equity issuance or balance sheet

What does this mean for Radius?

Opportunity to become a positive EBITDA and EPS company in 2022 with three pivotal orphan trials reading out in 2024 and 2025

This would be accomplished by executing on the following…

Our Focus

Abaloparatide

- Grow 90+% margin U.S. TYMLOS SC business
- Globalize abaloparatide: capture high-margin royalty and milestone cash flow

Elacestrant

- Assist in advancing with Menarini to maximize full patient opportunity
- Capture high-margin cash flow through milestones and royalties

RAD011

- Initiate three orphan pivotal studies with readouts in 2024 and 2025

Radius

Q&A